A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants

NCT03841630 · Completed

Last updated 2026-05-28

This study tests the safety of a single injection of the drug LY3437943 in healthy adults to check for any serious side effects.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 45 people

Who can join Ages 21–65 · all sexes Healthy volunteers accepted.

Timeline Started 2019-03 · est. completion 2019-07

Where 1 site · Singapore

What this study is testing ClinicalTrials.gov NCT03841630 ↗

Description as written by the study sponsor.

This study is being conducted to determine the side effects related to LY3437943 given as a single injection under the skin to healthy participants. Blood tests will be performed to check how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3437943 or placebo. The study will last up to approximately 71 days for each participant, including screening.

Treatments tested

LY3437943 Drug

Administered subcutaneously (SC)
Placebo Drug

Administered SC

Main thing measured	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03841630 ↗